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Abstract: Can hyperactivation of a few key signaling effectors be the underlying reason for
the majority of epithelial cancers despite different driver mutations? Here, to address this
question, we use the Drosophila model, which allows analysis of gene expression from tumors
with known initiating mutations. Furthermore, its simplified signaling pathways have numerous
well characterized targets we can use as pathway readouts. In Drosophila tumor models, changes
in the activities of three pathways, Jun N-terminal Kinase (JNK), Janus Kinase/Signal Transducer
and Activator of Transcription (JAK/STAT), and Hippo, mediated by AP-1 factors, Stat92E, and
Yorkie, are reported frequently. We hypothesized this may indicate that these three pathways are
commonly deregulated in tumors. To assess this, we mined the available transcriptomic data and
evaluated the activity levels of eight pathways in various tumor models. Indeed, at least two out of
our three suspects contribute to tumor development in all Drosophila cancer models assessed, despite
different initiating mutations or tissues of origin. Surprisingly, we found that Notch signaling is also
globally activated in all models examined. We propose that these four pathways, JNK, JAK/STAT,
Hippo, and Notch, are paid special attention and assayed for systematically in existing and newly
developed models.
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1. Introduction
1.1. Studying Tumorigenesis in Drosophila is Fast, Cheap, and Effective
Drosophila imaginal discs, larval precursors of adult epithelial tissues, are outstanding models of
epithelial tumorigenesis. Experiments in this system have contributed enormously to our molecular
and mechanistic understanding of cancer and to the development of treatments [1–3]. This contribution
ranged from mapping downstream effectors of cancer inducing mutations to understanding synergistic
interactions between driver mutations to building avatars for personalized drug screening [4–6].
For example, the Hippo tumor suppressor pathway was first discovered in flies [7–9]. The nuclear
effectors of this pathway, Yorkie (Yki) in Drosophila, Yes Associated Protein (YAP) and Transcriptional
Co-activator with a PDZ-binding Domain (TAZ) in mammals, are now established oncogenes [10,11].
Likewise, many components and signaling mechanisms of other pathways involved in cancer, such
as Wnt (Wingless in Drosophila), Bone Morphogenetic Protein (BMP), Notch (N), Epidermal Growth
Factor Receptor (EGFR)/Ras, Insulin, Janus Kinase/Signal Transducer and Activator of Transcription
(JAK/STAT), and Jun N-terminal kinase (JNK), were delineated using fly genetics [12–20]. It is
important to note that all these cancer pathways have developmental roles as well ranging from
cell fate specification to regeneration. They all contribute to regulation of basic cellular processes,
such as proliferation, cell growth, and apoptosis. To help the non-expert, we list the key pathway
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components and targets in Table 1 with a color code, where green is used for pro-growth/cancer and
red for anti-growth factors.
Table 1. Common pathway members and their activity read-outs. A brief introduction of the key
players of the pathways that were examined in this work. EGFR, Epidermal Growth Factor Receptor;
Dpp, Decapentaplegic; Hh, Hedgehog; Wg, Wingless; JNK, Jun N-terminal Kinase; Jak/Stat, Janus
Kinase/Signal Transducer and Activator of Transcription; Spi, Spitz; Vn, Vein; MAPK, Mitogen-Activated
Protein Kinase; Cic, Capicua; Pnt, Pointed; Aop, Anterior Open; ERK, Extracellular Signal-Regulated
Kinase; D, Delta; Ser, Serrate; Su(H), Suppressor of Hairless; Mam, Mastermind; E(spl), Enhancer
of split; NRE, Notch Response Element; NICD, Notch Intracellular Domain; Tkv, Thickveins; Put,
Punt; Mad, Mothers against Dpp; Med, Medea; Brk, Brinker; Shn, Schnurri; Dad, Daughters against
Dpp; Sal, Spalt; Omb, Optomotor Blind; Ptc, Patched; Smo; Smoothened; Ci, Cubitus interruptus; Arr,
Arrow; Dsh, Dishevelled; Sgg, Shaggy; Arm, Armadillo; βcat, Beta-catenin; dTCF, Drosophila T-cell
Factor/Pangolin; Nkd, Naked; Egr, Eiger; Grnd, Grindelwald; Wgn, Wengen; Hep, Hemipterous; Bsk,
Basket; Kay, Kayak; Jra, Jun-related antigen; Atf3, Activating transcription factor 3; Irbp18, Inverted
repeat binding protein 18 kDa; CEBPG, CCAAT Enhancer Binding Protein Gamma; Pdp1, PAR-domain
protein 1; puc, puckered; Mmp1; Matrix Metalloproteinase 1; TRE, Transcription Response Element;
Upds, Unpaireds; Dome, Domeless; Hop, Hopscotch; Ds, Dachsous; Crb, Crumbs; Wts, Warts; Yki,
Yorkie; Sd, Scalloped; Ex, Expanded; Diap1, Drosophila inhibitor of apoptosis protein 1; Ban, Bantam.
Pathway EGFR/Ras Notch Dpp Hh Wg JNK Jak/Stat Hippo
Ligand Spi,Vn D, Ser Dpp Hh Wg Egr Upds Ds
Receptor EGFR N Tkv,Put Ptc, Smo
Arr,
Fz Grnd, Wgn Dome
Fat,
Crb
Key
Players
Ras,
Raf,
MAPK
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Axin,
APC
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Bsk/JNK
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(Jak)
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Wts
Nuclear
Factors
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N,
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Brk,
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Ci
Arm/
βcat,
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Stat-92E YkiSd
Activity
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anti-dp-ERK
anti-Cic
pnt-lacZ
aos-lacZ
cic-GFP
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NRE-EGFP
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anti-NICD
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ptc-lacZ
anti-Cut
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anti-P-STAT
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The color coding indicates the positive (green) or negative (red) effect of the protein on tissue growth if known.
In 2005, the Cagan Lab published a Drosophila model of multiple endocrine neoplasia type 2
(MEN2). They used an active form of the Ret-kinase found in patients and expressed it constitutively
in larval eye discs [21]. This model was utilized to map downstream effectors and for pharmacological
screening, leading to an effective, Food and Drug Administration-approved treatment for the disease
within 6 years of the initial publication [22,23]. This approach has now been taken to the next level for
personalized medicine, where 5–15 driver mutations from a patient are introduced into a fly avatar.
These genetically personalized fruit flies are then used for drug screening [24]. This method has already
proven to work and helped a patient with metastatic colorectal cancer [4]. These examples highlight
the speed and power of Drosophila genetics for basic and translational cancer research.
1.2. Cooperation between Different Signaling Pathways Is a Hallmark of Tumorigenesis
Most tumors initiate as the result of multiple mutations arising, which synergistically cooperate
to transform normal cells to a tumor fate, conferring proliferative potential, invasive potential,
and resistance to cell death, among other characteristics [25,26]. Even in the rare cases where a single
mutation has the ability to transform a cell, this is achieved by misregulation of multiple downstream
signaling pathways. For example, the dominant mutations in the Ret receptor tyrosine kinase activate
the Ras/ERK, Src, and JNK pathways [21]. Another example is the larval discs that are homozygous
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mutants for apical-basal polarity determinants scribble (scrib) or discs-large (dlg), which form neomorphic
masses [27,28]. Transformation of these mutant discs is owing to critical changes that activate JNK and
Yki, leading to excess production of the JAK/STAT ligands Unpaireds (Upds) [29]. Finally, mutations in
the epigenetic silencers of the Polycomb Repressive Complex 1 (PRC1) cause excess growth when the
mutant clones are allowed to occupy the whole disc using the eyFLP-cell lethal system [30]. Notably,
some PRC1 components have redundant functions in growth and single mutants may not always yield
overgrowth [30]. Therefore, double mutant combinations were utilized; Psc-Su(z)2 chromosome is a
deletion that lacks two PRC1 components, Posterior sex combs (Psc) and Suppressor of zeste 2 (Su(z)2), as
well as an uncharacterized, non-conserved gene [30]. Similarly, the polyhomeotic (ph) locus is duplicated
and contains proximal and distal transcription units, ph-p and ph-d, respectively [31]. The allele used to
generate the ph tumors contains mutations in both ph-p and ph-d genes [32]. The activities of different
pathways were screened in PRC1 complex mutants and the JAK/STAT pathway was found to be
highly and consistently induced [30]. Accordingly, the Upd ligands were shown to be direct targets
of Polycomb silencing [30]. Another study found a requirement for Notch signaling in ph eye disc
tumors [33]. The ph tumors also activated the JNK pathway [34]. Therefore, deregulation of multiple
signaling pathways is a common feature of tumor formation.
In 2003, ground-breaking work by Richardson and Xu labs initiated the field of cooperative
tumorigenesis in Drosophila [35,36]. Unbiased genetic screens revealed apical-basal polarity loss as a
cooperating factor with activated Ras and N mutations [35,36]. Paradoxically, if mutations in scrib or
dlg genes arise in a patch of cells, the surrounding wild-type cells effectively eliminate the mutant cells,
via a process known as cell competition. For recent and excellent reviews of this process, see [37–40].
However, if these scrib mutations in patches are combined with activated Ras or Notch, the outcome is
aggressive and metastatic tumors [35,36]. With its clonal nature, this model more closely mimics the
human condition. Genetics and transcriptomics revealed that JNK, JAK/STAT, and Yki are the drivers
of tumorigenesis in RasV12 + scrib- tumors [41–46]. We set out to determine whether these three
pathways, or others, are commonly deregulated in Drosophila tumors of different initiating mutations.
2. Background and Approach
Is There a Common Signaling Signature of Tumorigenesis?
Since 2003, many labs have generated new combinations of genetic aberrations that drive tumor
formation, ranging from combined defects in major signaling pathways to lysosome or mitochondrial
dysfunction, or utilized the concept of cooperative oncogenesis to screen for novel synergistic
interactions (for recent, comprehensive reviews, see [2,37]). Each study looked into the authors’ favorite
pathways and biological processes; nevertheless, common features are evident. For example, the JNK,
JAK/STAT, and Hippo signaling pathways were very frequently mentioned, leading us to question if
their co-activation is truly a common feature underlying development of diverse tumors, or simply
a bias in the assays used. However, as noted above, deregulation of many of the developmental
signaling pathways has been implicated in tumor formation. Thus, to determine if a specific subset
of pathways is consistently activated across diverse tumor types, creating a common tumorigenic
signaling state, we performed a meta-analysis using available transcriptomic datasets of Drosophila
tumors. We assessed the activity levels of JNK, JAK/STAT, Hippo, Decapentaplegic (Dpp), Hedgehog
(Hh), Wingless (Wg), Notch, and EGFR/Ras pathways in tumors by surveying expression levels for
selected, validated targets for each pathway. It is important to look at multiple readouts to assess
pathway activity as the transcription of each gene can be and often is regulated by multiple pathways.
To acknowledge this caveat, we highlighted the target genes that are known to be targets of multiple
pathways in cyan in the figures.
Notably, only a few of the Drosophila tumor models have been subjected to transcriptomic
analysis. We compiled data from four cooperative tumorigenesis models, two single mutants that
lead to transformation, and two PRC1 tumors. We also included transcriptomic data from warts
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(wts) mutants, and Notch intracellular domain (NICD) expressing discs representing hyperplastic
overgrowth conditions.
We mined the transcriptomic data available for the following genotypes:
(1) dlg mutant wing discs, data from [29]. Wing discs that are homozygous mutant for dlg lose
polarity, leading to neoplastic overgrowth. Such discs are practically immortal and continue to
grow if transplanted to new hosts [47].
(2) scrib mutant wing discs, data from [29]. Dlg and Scrib act together in a complex and scrib mutant
wing discs phenocopy dlg mutants, about 70% of all genes that are differentially expressed in
dlg mutant wing discs are also differentially expressed in scrib discs; 311 upregulated and 263
downregulated genes [29].
(3) RasV12 + scrib-: This is the original and best studied cooperative tumorigenesis model. Three labs
have analyzed RasV12 + scrib- tumors from four different tissues utilizing transcriptomics [41,43,48].
Such tumors are neoplastic and metastatic [35,49].
(4) N + scrib-: A microarray analysis was performed on N + scrib- tumors revealing common as well
as unique changes compared with RasV12 + scrib- tumors in the eye [43]. These tumors express
NICD in scrib- mitotic clones. Transcriptomes of wing discs with N + scrib- tumors were also
published recently [50]. N + scrib- tumors are neoplastic in nature.
(5) Abrupt + scrib-: The zinc finger transcription factor Abrupt was identified as a scrib cooperating
oncogene in a screen [51]. Ectopic Abrupt expression has no discernable phenotypes on
differentiation and gives the cells a slight growth advantage, whereas Abrupt overexpression in
scrib- cells maintains cells in a progenitor-like state and prevents the formation of photoreceptors.
Eye discs with such cells are severely overgrown and neoplastic [51,52].
(6) Psc-Su(z)2 double mutants, members of the Polycomb Repressive Complex 1 (PRC1). These
mutations lead to dramatic overgrowth in eye and wing discs. The mutated tissues often maintain
their apicobasal polarity [29,30].
(7) polyhomeotic (ph) mutants (ph-p and ph-d double), member of the PRC1, which often display a
loss of polarity along with overgrowth [33]. Clones can be invasive, and display cooperative
tumorigenesis with RasV12 [33]. A small proportion of animals with ph clones in the eye can reach
adulthood and display overgrown eyes [33,53].
(8) capicua, warts (cic, wts) double mutants: Cic is the transcriptional repressor of EGFR/Ras
signaling [54]. The Ras/Raf/MAPK Kinase (MEK) cascade culminates in activation of
Mitogen-Activated Protein Kinase (MAPK), which targets Cic for degradation, allowing target
gene induction [55]. Wts kinase acts in the Hippo pathway [49,56–60]. In wts mutants, Yki is
stabilized and can accumulate in the nucleus and help induce expression of genes that drive cell
growth (such as Myc), proliferation (e.g., Cyclin E), as well as conferring apoptotic resistance
via induction of Diap1 [7,8,61]. Hippo signaling controls the transcriptional output of the Ras
pathway and their mutual disruption, as in cic,wts mutants, causes synergistic overgrowth in
larval discs [54]. Such discs stay hyperplastic and lose apical-basal polarity only at the very late
stages [54]. We have data for day 5 (prior to overgrowth) and with overgrown, heavily folded
day 9 discs [54].
(9) wts mutants at day 5 and day 9, data from [54]. These discs are hyperplastic owing to overactivation
of Yki.
(10) NICD-overexpressing wing discs display hyperplastic overgrowth, data from [50].
We exclusively used datasets generated from imaginal disc tissue where the fold change in tumor
versus a wild-type control was available. The only exception to this rule is the ph tumor dataset; in this
study, the tissue was subjected to Fluorescence-Activated Cell Sorting (FACS) prior to RNA-sequencing
and the fold changes in tumor cells labeled with Green Fluorescent Protein (GFP) were reported against
the neighboring GFP− cells [53]. We reported expression values in the figures below as fold change in
log2 (log2FC) compared with controls. As we are using these values as proxies for pathway activity, we
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are reporting all values that are differentially expressed (p < 0.05) without a fold change (FC) threshold.
The published ph dataset used a very stringent cut-off (padj < 0.01), and thus values for many genes
were not available, shown in dark grey in the figures. Finally, the various datasets are annotated to
different releases of the Drosophila genome. When genes of interest were not found, attempts were
made to query all known synonyms, but we cannot preclude that some genes may have been missed
owing to the annotation differences.
3. Analysis/Results
3.1. Tumors Cause Delayed Pupariation and Loss of Cell Fate Specification
Notably, a phenotype shared between all the conditions assessed in this analysis is the heavily
delayed pupariation, which manifests as giant larvae. This phenotype is known to be caused by excess
Drosophila insulin-like peptide 8 (Dilp8) production [62]. Dilp8 secreted from discs acts remotely on the
central brain to delay the transition to the pupal stage. As such, larval life is extended, in some cases
indefinitely, giving the tumors more time to grow [63,64]. Among the conditions we re-analyzed, dilp8
induction was consistently very strong, with the exception of the ph tumors, ranging from 3.23-fold in
RasV12 + scrib- leg discs to an over 1000-fold induction in RasV12 + scrib- wing discs (Figure 1). dilp8
is a verified Yki/Sd target gene, but it can also be induced by JNK or JAK/STAT activation [63–65].
Notably, in cases where Yki is not activated, such as in Psc-Su(z)2 mutants, dilp8 is still heavily induced,
showing that it can be induced independently of Yki activation (Figure 1).
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datasets owing to different cut-offs used by different groups. Abbreviations: Insulin like peptide 8, 
Ilp8; twin of eyeless, toy; eyeless, ey; eyes absent, eya; sine oculis, so; dachshund, dac; Embryonic Lethal 
Abnormal Vision, ELAV; atonal, ato; homothorax, hth; teashirt.tsh; senseless, sens; Distalless, Dll; vestigial, 
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Figure 1. Expression levels of dilp8 and cell fate deter inants in various tu or odels. Samples were
grouped according to their tissue of origin. Genes that act in the retinal determination network and their
downstream effectors are highlighted in yellow, whereas genes required for cell fate determination in
the wing are highlighted in blue. Three genes with developmental roles in both tissues are highlighted
in green. Gene expression is displayed as fold change in log2 (log2FC) compared with controls.
Color coding corresponds to a heatmap with a scale from −5 (dark red, downregulation) to 5 (dark
green, upregulation). The midpoint, 0, is white. Light grey cells represent non-significant changes with
p ≥ 0.05. Cells are shown in dark grey if the gene as not found in the datasets owing to different
cut-offs used by different groups. Abbreviations: Insulin like peptide 8, Ilp8; twin of eyeless, toy; eyeless,
ey; eyes absent, eya; sine oculis, so; dachshund, dac; Embryonic Lethal Abnormal Vision, ELAV; atonal, ato;
homothorax, hth; teashirt, tsh; senseless, sens; Distalless, Dll; vestigial, vg; nubbin, nub).
Another common feature across various tumors is the loss of cell fate specification. In eye
tumors, defects in photoreceptor differentiation can be easily revealed by Embryonic Lethal Abnormal
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Vision (ELAV) staining; such defects were reported for RasV12 + scrib-, Ab + scrib-, cic,wts, and ph
tumors [45,51,53,54]. We analyzed the expressions of the fate determinants for the eye (twin of eyeless,
toy; eyeless, ey: eyes absent, eya; sine oculis, so; dachshund, dac; ELAV; atonal, ato; homothorax, hth; teashirt,
tsh; senseless, sens;) and the wing tissue (hth; tsh; sens; Distalless, Dll; vestigial, vg; nubbin, nub). Neoplastic
tumors and PRC1 tumors showed significant downregulation of corresponding fate determinants
(Figure 1, yellow and blue boxes). These changes were less pronounced in wts mutant and NICD
overexpressing wing discs, as well as in cic,wts mutant discs (Figure 1). The antenna and the leg tumors
showed a signature similar to that of the eye tumors. Thus, we observe that not only is differentiation
lost (ato, sens, ELAV), but much of the early tissue identity program is also downregulated during or as
a result of neoplastic tumor formation in both wing and eye discs (Figure 1). We then investigated
the activity of different signaling pathways to assess if common processes are activated to block
development and promote tumorigenesis.
3.2. Inactivation of Hippo, Dpp, Hh, Wg, and Activation of JNK, JAK/STAT, and Notch Are Commonly Seen
in Tumors
EGFR/Ras pathway: Notably, two of the four cooperative tumorigenesis models are based on
activation of the EGFR/Ras pathway, and as expected, transcriptional feedback regulators of this
pathway Argos (Aos), Sprouty (Sty), and Sulfated (Sulf1) were significantly induced in RasV12 + scrib-
and cic,wts tumors (Figure 2). In addition to the negative feedback regulators of the pathway and its
transcription factor Pointed (Pnt), all of which are direct Cic targets, we included the newly identified
Cic target genes Ecdysone receptor (EcR), EGF spitz (spi), and Leucine-rich tendon-specific protein (Lrt) in
our analysis [54]. EGFR/Ras activity was largely unaffected in the Abrupt + scrib-, scrib, and dlg tumors.
The pathway activity was lowered in the N + scrib- and ph eye tumors. Thus, EGFR pathway activation
is a specific feature of a subset of tumors.
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Figure 2. Epidermal growth factor receptor (EGFR)/Ras activation is not a prerequisite for tumor
formation. Light purple highlights the transcription factors of the pathway. Note that pnt is a
transcription factor and also a transcriptional target of the pathway. Gene expression is displayed in
log2FC. Color coding corresponds to a heatmap with a scale from −5 (dark red, downregulation) to 5
(dark green, upregulation). Light grey cells represent non-significant changes with p ≥ 0.05. Dark grey:
the gene was not found in the dataset. n.e. = not expressed, the gene was in the data, but showed 0
reads. Abbreviations: Sulfated, Sulf1; Ecdysone receptor, EcR spitz, spi; argos, aos; sprouty, sty; Leucine-rich
tendon-specific protein, Lrt; pointed, pnt.
Dpp, Hh, and Wg pathways: The activities of each of these developmental pathways were very
low in all tumor models examined, with a few notable exceptions. The shutdown of these pathways is
likely to reflect defects in differentiation, known to occur in these tumors [51,53,54] (Figure 1).
For the Dpp pathway, all the target genes displayed are induced upon Dpp activation with the
exception of brinker (brk), which is shut down by Dpp signaling [66,67]. Therefore, induction of brk
transcription indicates low Dpp activity. On the basis of upregulation of this gene, Dpp signaling is
markedly reduced in RasV12 + scrib- and cic,wts tumors (Figure 3). Curiously, Dpp signaling is high in
ph eye disc tumors (Figure 3). Strikingly, we noticed that the secreted BMP antagonist short gastrulation
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(sog) [68,69] was upregulated in the RasV12 + scrib- transcriptomes. We queried this across the tumor
transcriptomes and found a strong correlation between sog expression and Dpp pathway activity. We
found that sog is upregulated in all tumors assayed, except ph, where it is strongly downregulated
(log2FC = −4.16). Therefore, sog upregulation offers a potential mechanistic explanation for the
observed downregulation of Dpp activity levels. Interestingly, sog transcript levels are not changed
and the Dpp activity is low in the Psc/Su(z)2 wing tumors; this difference to ph tumors may be owing to
different tissue types.
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Yki localization, other good readouts for Yki activity in imaginal discs are expanded(ex)-lacZ, Diap1-
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Figure 3. Tumors display a trend of overall suppression of Dpp, h, and g path ays. The target
genes that are suppressed by the pathway are shown in bold, and pathway inhibitors are shown in red.
Light purple highlights the transcription factors of each pathway. brk meets all three criteria. In the
case of the Hh and Wg pathways, the ligands are also shown and highlighted in light purple, their
expression is not necessarily regulated by their own pathway, but their excess production can activate
their respective pathway. dpp is a transcriptional target of Hh signaling and is shown in that section.
Gene expression is displayed in log2FC. Color coding corresponds to a heatmap with a scale from −5
(dark red, downregulation) to 5 (dark green, upregulation). Light grey cells represent non-significant
changes with p ≥ 0.05. Dark grey: the gene was not found in the dataset. n.e. = not expressed, the
gene was in the data, but showed 0 reads. Abbreviations: Daughters against Dpp, Dad; Dorsocross 1-3,
Doc1-3; bag of marbles, bam; crossveinless-2, cv-2; brinker, brk; Mothers against Dpp, Mad; Medea, Med; short
gastrulation, sog; knot, kn; collier, coll; cut, ct; naked, nkd; arrow, arr; Drosophila T cell factor, dTCF; pangolin,
pan; armadillo, arm.
For the Hedgehog pathway, most pathway members/targets assessed were lower or unchanged in
tumors, suggesting there may be little flux through this pathway in tumors. A notable exception is
the upregulation of dpp ligand expression in scrib, dlg, and PRC1 tumors. It is not clear at this level of
analysis if dpp expression in these cells is dependent on Hh signaling or induced by a different factor.
Similarly, the activity of the Wg pathway is downregulated in most of the tumors assayed
except the PRC1 tumors and NICD-expressing discs. Wg expression is known to be regulated by N
signaling [70,71]. In the PRC1 tumors, Wg signaling is likely induced in the presence of excess ligand
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production (Wg, Wnt4, and Wnt6), highlighting another difference between PRC1 tumors and the
others we analyzed.
Our analysis supports the idea that, in most neoplastic tumors, normal developmental signaling
is not functioning. However, it highlights that the PRC1 tumors may be largely different from the more
neoplastic tumors assessed. Interestingly, Torres et al. performed a hierarchical clustering between ph
tumor transcriptomes and other known normal and tumor transcriptomes. This analysis demonstrated
that the ph tumors were more similar to embryonic signatures rather than other tumors (e.g., RasV12 +
scrib-), which were very dissimilar from embryonic signatures [53].
Hippo pathway: Despite the impressive overgrowth phenotypes of hippo mutant imaginal discs,
the involvement of the Hippo signaling pathway is not assayed for consistently in tumor models.
Only one out of every four papers that deal with tumor models reported on Hippo activity levels.
The first member of the Hippo cascade, Warts (Wts) kinase, was described as a tumor suppressor in
flies in the 1990s [72,73]. Wts stayed as an orphan kinase until the discovery of Salvador and Hippo
in the early 2000s [49,56–60,74]. Since then, the Hippo signaling cascade has well reached adulthood
and has proven itself as a key regulator of cell division and stemness in many contexts [9–11,75,76].
Yki is the main transcriptional mediator of this tumor suppressor pathway. Inactivation of the Hippo
pathway leads to activation of Yki and subsequent tissue growth [77]. Yki localization is linked to
pathway activity. Yki can accumulate in the nucleus only after the Hippo pathway is shut down [77].
Therefore, subcellular Yki localization and sensitivity to yki gene dosage are good assays for testing
involvement of the Hippo pathway. It is trickier to interpret experiments where yki-RNAi is shown to
suppress tumor growth as yki-RNAi prevents proliferation of normal cells as well. In addition to Yki
localization, other good readouts for Yki activity in imaginal discs are expanded(ex)-lacZ, Diap1-lacZ,
and the bantam sensor [57,78–80]. In RNA-seq experiments, the target genes ex, kibra, and dilp8 are
particularly robust readouts, whereas CycE, Myc, and Diap1 are upregulated more mildly, about 1.5-fold
in wts mutant discs (Figure 4 and Figure 9). Notably, high levels of F-actin are a well characterized and
potent activator of Yki [81,82]. Therefore, tumors where actin accumulation was observed may have
higher Yki activity [51,52,83–86].
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Figure 4. Yorkie activation contributes to tu ri e esis i odels with polarity loss. Light purple
highlights the nuclear factors of the pathway. Target genes that are known to also be regulated by other
pathways are highlighted in cyan. Gene expression is displayed in log2FC. Color coding corresponds to
a heatmap with a scale from −5 (dark red) to 5 (dark green). Light grey cells represent non-significant
changes with p ≥ 0.05. Dark grey: the gene was not found in the dataset. Abbreviations: Insulin like
peptide 8, Ilp8; diminutive, dm; expanded, ex; warts, wts; division abnormally delayed, dally; scalloped, sd;
yorkie, yki.
In our meta-analysis of sequenced tumors, Yki target genes were expressed in all tumors at levels
similar to those observed in wts mutants, except for the PRC1 tumors. As wts loss leads to constitutive
Yki activation, this should represent a strong induction of validated targets. In RasV12 + scrib- tumors,
Yki activation was less obvious in eye disc tumors compared with other tissues (Figure 4). Thus, Yki
activation is a broad, but not ubiquitous phenomenon in tumors. In light of this, it is possible to
speculate that Yki activation status in a tumor may be a potent way to stratify tumors that activate
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distinct sets of pathways to promote their growth. Tumors that do not activate Yki may become
neoplastic via a different mechanism and may behave quite differently from those that do activate Yki.
JNK pathway: The JNK pathway is stimulated by the Tumor Necrosis Factor (TNF)-type
ligand Eiger binding to its receptors Wengen and Grindelwald, which activate a MAP kinase
cascade that ultimately phosphorylates the downstream Jun-kinase Basket (Bsk) [87–92]. Bsk in
turn activates numerous AP-1 and AP-1 related b-Zip transcription factors. In Drosophila tumors,
the b-Zip transcription factors Jra, Kay, Atf-3, Pdp1, and Irbp18 have been implicated as potential
effectors [41,43,44,50,93,94].
JNK pathway activity is well monitored in tumors; 30 out of 40 recent papers we analyzed across
various tumor models directly assayed for JNK activity in their models and with good reason. JNK
signaling is activated in response to stress and tumor formation is no doubt a source of stress for
the tumor initiating cell and its neighbors [17,18]. Whereas JNK activation can be anticipated in the
presence of tumors, the outcome of JNK activation is not easily predicted. One of the JNK target
genes, Matrix metalloproteinase 1 (Mmp1), can lead to basement membrane degradation, and hence is
associated with invasive behavior [44]. Moreover, JNK activation in a cell can induce autonomous and
cell non-autonomous proliferation via induction of the Upd ligands [19]. Finally, it can also induce
autonomous cell death via induction of the pro-apoptotic gene reaper (rpr) [19].
In our analysis of the literature, we observed that the outcome of JNK signaling in tumors can
be as diverse as cellular responses to it. For comprehensive reviews of pro- and anti-tumorigenic
roles of JNK signaling, see [19] and [95]; however, we will briefly summarize some highlights here.
JNK induction is commonly a contributing factor to tumor growth and metastasis, as co-expression
of a dominant-negative version of JNK (Bsk-DN) can suppress tumor growth and invasion in
RasV12 + scrib- and N + scrib- tumors [44,46,48]. In ph tumors, co-expression of Bsk-DN reduces
the volume of mutant clones [34]. Similarly, JNK activity is induced and co-expression of Bsk-DN
can suppress tumorigenesis in Ras + Pico [96], Ras + Src [83,97], and activated N + Src [98] models.
However, in some tumors, tumor growth and invasive potential can be uncoupled from each other.
In Ab + scrib- tumors, co-expression of Bsk-DN suppresses the invasive behavior, but not the tumor
growth [51]. In contrast, the tumors are even larger owing to an extended larval life, but have a more
hyperplastic appearance [51]. Therefore, it is possible to achieve excessive overgrowth independently
of JNK, however, invasive behavior is tightly linked to high JNK activity.
Finally, we came across two other studies where JNK activation may have a tumor suppressive
quality because co-expression of Bsk-DN actually enhances the overgrowth observed; that is, eyeful
tumors [99] and the polyploid tumors formed by cooperation between cytokinesis failure and activated
Ras or Yki expression [100]. Therefore, the outcome of JNK activation is very much context-dependent.
Many other studies reported JNK induction in their respective tumor models, but did not assess the
nature of JNK contribution.
The JNK pathway was globally induced in all tumors and hyperplastic discs that were subjected
to transcriptomics (Figure 5). This induction is rather strong and clear in all tumors with the notable
exception of the cic,wts tumors at day 5 (Figure 5). At this stage, cic,wts discs are only slightly overgrown
and retain their apical-basal polarity. Mmp1 and upd1–3 ligands are further induced at day 9 cic,wts
tumors, but this induction is still relatively mild compared with other tumors and more similar to
JNK activity levels in wts mutant discs. Therefore, JNK activity seems to increase over time in the
cic, wts model. The same trend was also observed in the RasV12 + scrib- eye tumors [42]. As more
single cell sequencing data emerges, it will be interesting to see if this trend is biologically relevant,
or if it is simply a reflection of the shifted ratio of tumor to normal cells in older tumor samples in
bulk RNA-seq experiments. If it is biologically relevant, it will be interesting to find if this is a general
trend for all tumors and whether there is a threshold of JNK activity where invasive behavior can be
initiated. We observe that JNK activation is a common feature, but with conflicting outcomes. Thus,
we advocate that pathway activity be assessed, but also blocked in tumors going forward to assess if
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JNK has pro-tumorigenic or tumor suppressing functions in each context. Increased data points may
paint a clearer picture of how the tumor context or progression correlates with JNK function.
Figure 5. Activation of JNK is a common feature of all tumor models analyzed. Light purple highlights
nuclear factors of the JNK pathway. Target genes that are known to also be regulated by other pathways
are highlighted in cyan. Gene expression is displayed in log2FC. Color coding corresponds to a heatmap
with a scale from −5 (dark red) to 5 (dark green). Light grey cells represent non-significant changes with
p ≥ 0.05. Dark grey: the gene was not found in the dataset. n.e. = not expressed, the gene was in the
data, but showed 0 reads. Abbreviations: ftz transcription factor 1, ftz-f1; cheerio, cher; outstretched, os; Ets
at 21C, Ets21c; Paxillin, Pax; kayak, kay; Activating transcription factor 3, Atf3; CCAATT Enhancer Binding
Protein Gamma, CEBPG; Inverted repeat binding protein 18, Irbp18; Jun-related antigen, Jra; PAR-domain
protein 1, Pdp1.
JAK/STAT pathway: The workings of the JAK/STAT pathway are relatively simple.
The interleukin (IL)6 type ligands Upd1 (that is, os), Upd2, and Upd3 bind to their receptor Domeless,
which stimulates its dimerization and activation of the associated Janus Kinase (Jak) molecule Hopscotch
(Hop). Hop, in turn, phosphorylates the sole Stat ortholog in Drosophila, Stat92E [20]. Activation of
Stat92E promotes the growth, proliferation, invasion, and survival of tumor cells [41,42,45,101].
The ligands upd1, 2, and 3 are often upregulated in tumors, whereas the other pathway components
are not differentially expressed [29,41].
JAK/STAT activity can be assessed by expression of its best studied target gene, Suppressor of
Cytokine Signaling at 36E (Socs36E) in various contexts [42,65,102–104]. Socs36E acts as a feedback
inhibitor of the pathway and can be used to test the contribution of JAK/STAT activity to tumors.
Co-expression of UAS-Socs36E can suppress PRC1 tumors [30], overgrowth of dlg homozygous mutant
discs [29], and the Hippo/Ras synergy [54]. Likewise, Davie et al. demonstrated that null mutations
in Stat92E strongly suppressed the excessive growth of RasV12 + scrib- eye tumors [42]. Finally,
introducing heterozygosity for Stat92E into the tumor background reduced the size of Psc-Su(z)2
eye tumors [30]. Thus, in all reported cases, excess JAK/STAT activity contributes to tumor growth.
Ptp61F, a protein tyrosine phosphatase, is another negative regulator and transcriptional target of the
pathway [42,105,106]. Interestingly, Socs36E and Ptp61F are already broadly upregulated in tumors,
leading us to speculate that the aggressive phenotypes observed would be more severe if these genes
were mutated or downregulated.
Several other direct targets of the pathway have been identified and verified by the Bach Lab
over the years, including chronologically inappropriate morphogenesis (chinmo), cap-n-collar (cnc), lamina
ancestor (lama), Zn finger homeodomain 2 (zfh2), NADPH oxidase (Nox), Keap1 I (Keap1), and pannier
(pnr) [65,101,107,108]. Among these, Nox, Keap1, and pnr are negatively regulated by the pathway
and thus are shown in bold and traced in red (Figure 6). CG1572 was identified as an effector of the
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pathway in hematopoietic tumors [104]. terribly reduced optic lobes (trol), which encodes a Perlecan, is
regulated by the pathway in multiple tissues [42,107]. Finally, an embryonic target gene dorsal (dl) was
identified as a likely direct Stat92E target gene and had more accessible chromatin in RasV12 + scrib-
eye tumors and Upd overexpressing eye discs [42,109]. In agreement with the published results, these
selected target genes indicated increased JAK/STAT activity in nearly all tumor models examined as
well as the hyperplastic wts mutant, and NICD-expressing discs (Figure 6). In the case of scrib, Ab
tumors, about half of the target genes indicate pathway activation, whereas the rest strongly argue the
opposite, preventing us from reaching a verdict.
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Figure 6. Most tumors have high levels of JAK/STAT activity. The target genes that are suppressed by
the pathway are shown in bold, and pathway inhibitors are shown in red. Light purple highlights the
transcription factor of the pathway. Gene expression is displayed in log2FC. Color coding corresponds
to a heatmap with a scale from −5 (dark red) to 5 (dark green). Light grey cells represent non-significant
changes with p ≥ 0.05. Dark grey: the gene was not found in the dataset. Abbreviations: Suppressor of
Cytokine Signaling at 36E, Socs36E; Protein tyrosine phosphatase 61F, Ptp61F; chronologically inappropriate
morphogenesis, chinmo; cap-n-collar, cnc; lamina ancestor, lama; Zn finger homeodomain 2, zfh2; terribly reduced
optic lobes, trol; dorsal, dl; NADPH oxidase, Nox; Keap1, Keap1; and pannier, pnr.
Our analysis was also inconclusive in ph tumors despite higher levels of Upds, but these tumors
are known to have high JAK/STAT activity [30,34]. Previous studies have shown that tumor produced
Upds stimulate JAK/STAT signaling in the neighboring cells [19,45,110]. In the ph dataset, gene
expression in tumor cells was compared to that of non-tumor neighbors [53], which likely also have
high JAK/STAT activity. Thus, this approach may have filtered out the differential expression of Stat
target genes. Upds are transcriptional targets of JNK signaling, thus JNK activation should cause
activation of JAK/STAT signaling. Indeed, this seems to be the case, with the exception of the Ab + scrib-
model, where many JNK targets are induced, but not the Upds (Figure 5). This observation was rather
surprising considering that Yki and JNK are both active in this tumor, and Upd3 is a known cooperative
target of these pathways [29,51]. However, as noted above, JNK’s function in Ab + scrib- tumors is
pro-invasive, but not pro-growth. As JAK/STAT signaling is a potent pro-growth pathway, it is possible
that this model, in which we observe an uncoupling of JNK + Yki from JAK/STAT activation, could be
an important system in which to gain further insights into cross talk between these pathways in tumors.
It would be interesting to examine if the upd promoter regions are accessible in these tumors. Therefore,
why the JAK/STAT pathway is not activated in this tumor is quite interesting, but the mechanism
remains unknown.
Notch pathway: Activation of Dpp, Hh, and Wg pathways as well as EGFR or N signaling
can induce cell proliferation and hyperplastic tissue growth, apart from and in addition to their
roles in differentiation. The amount of growth that can be induced is especially impressive upon N
activation [71]. However, what regulates the switch between differentiation and proliferation control
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is often poorly understood. In the case of Ras signaling, co-activation of Yki was proposed to shift
the balance towards proliferation [54]. Pathways involved in cell fate specification in imaginal discs,
Dpp, Hh, and Wg showed overall lower activity in tumors (Figure 3). On the contrary and to our
surprise, we find that N signaling seems to be activated in all tumors examined (Figure 7). This is less
clear from our target analysis in the case of the ph tumors (Figure 7), however, Notch activation was
experimentally validated in these tumors [33,34].
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jitterbug, jbug; Lactate dehydrogenase, Ldh; C-terminal Src kinase, Csk.
In Drosophila, Notch activation has been identified as being able to cooperate with both the loss of
scribble or the activation of Src to promote tumor development [48,50,98]. Src activation synergizes
with N in inducing hyperplastic growth in eye and wing discs, and leads to JNK activation [98].
In combination with scrib loss, N activation leads to neoplastic and i vasive tumors [48]. bHLH
transcription factors deadpan (dpn) and the Enhancer of Split (E(spl)) genes are the best characterized
and direct target g nes for N during differentiation, however, these canonical N targets re sometimes
downregulated in N induced tumors [71,98]. Indeed, in N + scrib- tumors, only 3 out of 13 of these
bHLH factors were induced (Figure 7). Expression of E(spl) genes was broadly downregulated in
diverse tumor types (Figure 7). Ho et al. reported that Src can inhibit transcription of E(spl) genes [98].
Thus, we also checked Src levels, but overall found them to be lower in tumors (Figure 7). Therefore,
reduced E(spl) transcription is not owing to higher Src levels in these tumors.
N signaling is peculiar as the receptor N is also the transcription factor of the pathway. Upon ligand
binding, N undergoes a series of cleavages and its intracellular domain, NICD, translocates into the
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nucleus. N forms a complex with Suppressor of Hairless (Su(H)) and Mastermind, to induce
transcription of Notch-responsive genes [14,111]. The Bray lab mapped Su(H) binding sites genome
wide and asked which genes were induced upon N activation in Drosophila cells and in wing disc
tumors, defining additional direct N target genes [71,112]. Instead of the canonical N target genes,
a whole set of other genes was induced during N hyperplasia; 58 genes were commonly induced
in NICD and Su(H) expressing overgrown discs and had Su(H) binding in their vicinity [71]. Of
these 58, 9 representative target genes (Serrate, Ser; Kank; zormin; fruitless, fru; CG6191; CG3835;
CG18507; pickled eggs, pigs; and jitterbug, jbug) are shown in Figure 7. The rate-limiting enzyme in
glycolysis, Lactate dehydrogenase encoded by ImpL3/Ldh, was also shown to be a direct N target
placing glucose metabolism downstream of N activity, and hence was included in our analysis [113]).
These ten readouts were broadly activated in all the tumors assessed as well as in wts mutant discs
and NICD-expressing discs (Figure 7). We noted that about 20% of N targets in tumors are also high
confidence Yki/Sd targets [41,71]. These included target genes that are regulated by both the Hippo
and JNK pathways: chinmo, ftz-f1, upd2, and upd3 loci. These loci are some of the most highly and
consistently upregulated genes across tumors we assessed, raising the possibility that Notch activation
also contributes to promoting the robust upregulation of these important genes. Clearly, these results
indicate that there remains much to be discovered about the role of Notch signaling in these tumors,
and its possible relationships with AP-1, Stat, and Yorkie dependent gene expression.
3.3. A Set of Transcription Factors Is Commonly Upregulated in Tumors
From the available transcriptomics studies, several transcription factors have also been identified
as key regulators of tumor progression/gene expression primarily downstream of these pathways.
We decided to also query these transcription factors to see if their upregulation was a common
feature. Thus, we examined the expression of selected AP-1 transcription factors (Kay, Atf3, Irbp18, Jra,
Pdp1), Myc, Ftz-f1, Ets-21C, Chinmo, Abrupt, and the repressor Cic (Figure 8). Interestingly, cic was
downregulated in most tumors to a similar degree as it was by mutation in the cic,wts model. ftz-f1,
an ortholog of the human orphan nuclear receptor 5A (NR5A), was mildly to strongly upregulated
in nearly every model. Atf3 and Pdp1 were also notably upregulated as well as Ets21C and chinmo.
The broad upregulation of these factors may suggest that they bear further investigation in other
emerging models as each has orthologs that have been implicated in human tumorigenesis.
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Finally, we also analyzed the expression of apoptosis and cell cycle regulators in the tumor models.
In agreement with the literature, wts and cic,wts mutant discs had higher levels of the anti-apoptotic
gene Diap1 and lower levels of the pro-apoptotic gene reaper (rpr), protecting them from cell death
(Figure 9) [8,114]. Furthermore, CycE and String (Stg), rate limiting factors in cell cycle, were
induced in wts and cic,wts discs, leading to excess cell divisions (Figure 9) [9]. NICD expressing
discs behaved similarly (Figure 9). The other tumors seemed to have overall higher expression of
the pro-apoptotic genes and reduced levels of the cell cycle genes, which appeared counterintuitive
given their proliferating state (Figure 9). High rpr expression can be attributed to JNK activity,
however, regulation of grim in RasV12 + scrib- tumors begs for further attention, as it was consistently
induced in all four tissues (Figure 9). The upregulation of these regulators of apoptosis may be
relevant to the “undead” phenomenon of sublethal caspase activation reported in Ras-dependent
tumors [97,115]. Alternatively, this may reflect cell death induction in either the tumor or neighboring
cells. Future single-cell experiments may be able to better differentiate the role of these genes and
the apoptotic pathways in the growth or restraint of the tumor, as this analysis cannot differentiate
autonomous versus non-autonomous gene induction and is limited by the single time point.
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Figure 9. Expression of genes involved in apoptosis and cell cycle across tumors. Gene expression
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4. Discussion and Conclusions
In the quest to develop better therapeutic approaches, there has been a push towards personalized
medicine based on patients’ mutational status. The use of sophisticated statistical and computational
analyses of genomic data from human tumors revealed large numbers of candidate genes and variants.
While this has yielded some clear gains, it is often tough to interpret this big cancer data and to translate
it to improved patient care [116]. The way forward will be paved by functional studies in experimental
models to reveal the biological significance of the newly identified variants [117]. Here, we sought
to determine if tumors with different known initiating mutations share common cell biology in the
form of signal pathway activity. If so, this may indicate that unique mutational signatures converge on
common signaling states to create tumors. By identifying common core signaling states, tumors may
be stratified for potential treatment with novel inhibitor combinations. Owing to its demonstrated
successes as an initial discovery platform as well as a translational model for tumor therapies, insights
from Drosophila will continue to be informative in the age of personalized cancer medicine.
We observe in our meta-analysis that, while not a rule, Hippo pathway is inactivated, whereas
Notch, JNK, and STAT signaling pathways are frequently co-activated in Drosophila tumors (Figure 10).
It is already known that co-activation of Yki and JNK can synergistically activate upd expression, leading
to Stat activation [29]. It would be interesting to know if there is additional cross-regulation between
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the pathways, which could lead to a self-sustaining circuit in tumors that makes them independent of
initiating mutations once the circuit of JNK/Yki/Stat is established.
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e were surprised to discover that the data we analyzed supported that the Notch pathway is
also commonly activated in different models. To ur knowledge, it s not known if Notch signaling is
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w uld bec me activated in, for example, RasV12 + scrib- or cic,wts tumors. Further e, interaction of
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hile activation of Yki, JAK/STAT, and JNK is com only observed in tumors, deregulation of all
three simultaneously is not a bligate scenario. As noted, PRC1 tumors did not activate Yki, wh reas
upregulation of Upds and JAK/STAT induction is uniquely missing in Ab + crib- tumors. Our analysi
suggests that the ph tumors activate Dpp and Wg athways, unique amo g the tumors assessed.
This tumor al o showed a signature that was quite similar to nor al embryonic g ne expressio ,
r presenti g a very different kind o tumor [53]. Overall, with the f equent exception of th ph tumors,
the key factors induced are chinmo, Ets21C, ftz-f1, Atf3, and Pdp1, forming a common tumor signature
found across tumors with different initiating mutations (Figure 8). Further documentation of which
tumors do or do not rely on the Yki/Stat/AP-1 axis could yield a new broader way to stratify tumors.
In turn, it is possible this insight could lead to simplified or more effective treatment strategies.
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